Published in Oncol Res on January 01, 1993
Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med (2011) 0.87
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
Factors affecting the long-term results of endodontic treatment. J Endod (1990) 3.45
CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature (2001) 2.47
Positive regulation of T cell activation and integrin adhesion by the adapter Fyb/Slap. Science (2001) 1.87
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract (2013) 1.55
Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy (2004) 1.41
Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res (1969) 1.26
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol (1999) 1.16
Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances. Biochem J (1974) 1.15
Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (1980) 1.00
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
Modification of tumor regression by immunologic means. Cancer Res (1969) 0.99
Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res (1988) 0.97
Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon. Cancer Res (1987) 0.93
Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res (1992) 0.91
The effect of different types of composite resin fillings on marginal gingiva. J Clin Periodontol (1987) 0.90
Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract (2010) 0.89
Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res (1984) 0.89
Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1978) 0.89
Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res (1989) 0.89
Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res (1992) 0.88
Effects of anticancer drugs on the immune system in humans. Semin Oncol (1989) 0.88
Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res (1977) 0.88
Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer (1994) 0.88
Toxicological and antiproliferative effects of N6-(delta2-isopentenyl) adenosine, a natural component of mammalian transfer RNA. Cancer Res (1970) 0.87
Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer (2000) 0.87
Immunosuppressive effects of methylglyoxal-bis(guanylhydrazone) on mouse bone marrow and spleen cells and their antagonism by spermidine. Biochem Pharmacol (1978) 0.87
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res (1986) 0.86
Sens-A-Ray. A new system for direct digital intraoral radiography. Oral Surg Oral Med Oral Pathol (1992) 0.86
A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1. Int J Immunopharmacol (2000) 0.85
Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res (1989) 0.85
Doxorubicin-induced DNA degradation in murine thymocytes. Mol Pharmacol (1994) 0.85
Awareness of periconceptional folic acid supplementation among Nepalese women of childbearing age: a cross-sectional study. Prev Med (2012) 0.84
Selective modulation by alpha-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts. Cancer Res (1986) 0.84
Establishment and characterization of a new murine cell line (SR-4987) derived from marrow stromal cells. Cytotechnology (1992) 0.84
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1998) 0.83
Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. J Leukoc Biol (2001) 0.83
The guanine-nucleotide exchange factor Vav is a crucial regulator of B cell receptor activation and B cell responses to nonrepetitive antigens. J Immunol (1999) 0.82
Fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse. Cancer Res (1975) 0.82
Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. Int J Immunopharmacol (1982) 0.81
Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res (1988) 0.81
Effect of splenectomy on the regression of transplantable tumors. Cancer Res (1968) 0.81
Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. Int J Immunopharmacol (1982) 0.81
Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol (1983) 0.81
The clinical toxicity of anticancer drugs and its prediction. Semin Oncol (1977) 0.81
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother (1996) 0.80
Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res (1972) 0.80
Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer (1995) 0.80
Plasma membrane as a site for chemotherapeutic intervention. Adv Enzyme Regul (1978) 0.80
Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother (1995) 0.79
Toxic and patologic effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone), a new antileukemic agent. Cancer Res (1969) 0.79
Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity. FASEB J (2001) 0.79
Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. Int J Immunopharmacol (1988) 0.79
Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer (1998) 0.79
Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine. Cancer Res (1969) 0.79
Lipopolysaccharide and splenic tumoricidal macrophage activation. J Leukoc Biol (1994) 0.79
Expression of B cell markers on SR-4987 cells derived from murine bone marrow stroma. Exp Hematol (1997) 0.78
Development of gingivitis around different types of composite resin. J Clin Periodontol (1987) 0.78
Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. Cancer Res (1972) 0.78
Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions. Cancer Immunol Immunother (1990) 0.78
Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res (1999) 0.78
Induction of suppressor T cells in culture--I. Cell-cell interactions. Int J Immunopharmacol (1984) 0.78
Selective effects of Adriamycin on murine host defense systems. Immunol Rev (1982) 0.78
Penetration of metallic ions from restorations into teeth. J Prosthet Dent (1968) 0.78
Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol (1995) 0.78
Polymyxin B-mediated lysis of tumor cells. Int Arch Allergy Immunol (1993) 0.78
The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol (1983) 0.78